Invivyd (IVVD) shares fell past 12% in recent Tuesday trading after the biopharmaceutical company withdrew prior revenue guidance.
The company said the move was "due to recent growth headwind from US FDA's late-Q3 2024 warning on potential for substantially reduced activity of pemivibart through the Pemgarda Fact Sheet and other media based on contested, third-party, non-peer-reviewed, non-reproducible, virologic activity data from a non-pemivibart antibody."
The company previously guided to $150 million to $200 million in Pemgarda net product revenue in 2024 and expected to finish the year with $75 million or more in cash and cash equivalents.
Invivyd said its preliminary net product revenue now stands at $9.3 million for Q3 from Pemgarda, and it estimates it ended the quarter with about $107 million in cash and equivalents.
Price: 0.93, Change: -0.12, Percent Change: -11.06
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.